Section Arrow
ROIV.NASDAQ
- Roivant Sciences Ltd
Quotes are at least 15-min delayed:2026/06/06 12:08 EDT
Regular Hours
Last
 28.58
-0.95 (-3.22%)
Day High 
29.64 
Prev. Close
29.53 
1-M High
32.7925 
Volume 
4.64M 
Bid
28.1
Ask
30.25
Day Low
28.56 
Open
29.51 
1-M Low
27.85 
Market Cap 
21.24B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 29.55 
20-SMA 29.39 
50-SMA 28.69 
52-W High 32.7925 
52-W Low 10.705 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.54/-1.46
Enterprise Value
21.34B
Balance Sheet
Book Value Per Share
6.29
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
8.26M
Operating Revenue Per Share
0.11
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
BCDABioCardia Inc.1.03+0.111+12.08%-- 
BGMSBio Green Med Solution Inc1.5+0.44+41.51%0.3PE
CMNDClearmind Medicine Inc.3.98+1.07+36.77%-- 
ADTXAditxt Inc.0.0621-0.0149-19.35%-- 
RXRXRecursion Pharmaceuticals3.315-0.485-12.76%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.